T1	Participants 466 477	38 patients
T2	Participants 627 638	third group
T3	Participants 678 686	patients
T4	Participants 774 780	groups
T5	Participants 914 924	recipients
T6	Participants 1037 1045	patients
T7	Participants 1053 1060	C group
T8	Participants 1212 1234	GAN, VAL, and C groups
T9	Participants 1423 1446	GAN, VAL, and C groups,
T10	Participants 1638 1660	GAN, VAL, and C groups
T11	Participants 1785 1792	patient
